The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation. 

Screening for the drug necessitated a PET scan, and individuals also required a baseline MRI within one year before treatment, with more to follow. 

The feature effectively allows the ultrasound systems to operate hands-free.

Heart teams have several options when patients present with stable chest pain and require further testing. According to a brand new analysis of nearly 800 patients, CCTA may be the best place to start. 

There is significant variation from one radiologist to the next in suggesting follow-up head and neck imaging, Harvard experts detailed in AJR. 

The nonprofit patient-safety organization says the list “reflects our judgment about which risks should be given attention now to help care providers, as well as device manufacturers, prioritize their patient safety efforts.”

New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.